"45 ||| Materials and methods ||| 2.27 ||| On discharge from the hospital, the woman's preference for the oral or vaginal misoprostol formulation was evaluated by asking which formulation she would prefer should labor induction be required in a future delivery.",discharge hospital womans preference oral vaginal misoprostol formulation evaluated formulation prefer labor induction required future delivery,C0012621|C0019994|G0000000|C0558295|C0442027|C0042232|C0085174|C0524527|C0220825|C0524527|G0000000|C0022864|C0205263|C1514873|C0016884|C0011209
"70 ||| Results ||| 3.7 ||| The same was true for vaginal delivery not achieved within 24 hours, uterine hyperstimulation, and cesarean delivery.",true vaginal delivery achieved 24 hours uterine hyperstimulation cesarean delivery,C0205238|C0042232|C0011209|G0000000|C0450371|C0439227|C0042149|G0000000|C3841297|C0011209
84 ||| Results ||| 3.21 ||| There were no cases of neonatal encephalopathy or death.,neonatal encephalopathy death,C1552240|C0006111|C0011065
"89 ||| Discussion ||| 4.4 ||| By contrast, with oral misoprostol, the frequency of vaginal delivery not achieved within 12 hours was only 26% in the first randomized clinical trial assessing this route of administration [8].",contrast oral misoprostol frequency vaginal delivery achieved 12 hours 26% randomized clinical trial assessing route administration 8,C0009924|C0442027|C0085174|C0376249|C0042232|C0011209|G0000000|C0450371|C0439227|C0450371|C0034656|C0205210|C0008976|C1516048|C0013153|C0001554|G0000000
"47 ||| Materials and methods ||| 2.29 ||| A non-reassuring fetal heart rate (FHR) pattern, evaluated using cardiotocography or intermittent fetal auscultation, was defined as the persistence of a baseline FHR of less than 110 bpm, presence of late FHR decelerations (reduction in FHR following uterine contractions), or presence of fetal tachycardia (persistent FHR of more than 160 bpm) [19].",non-reassuring fetal heart rate fhr pattern evaluated cardiotocography intermittent fetal auscultation defined persistence baseline fhr 110 bpm presence late fhr decelerations reduction fhr uterine contractions presence fetal tachycardia persistent fhr 160 bpm 19,C1518422|C0015965|C0018787|C0871208|G0000000|C0449774|C0220825|C0007208|C0205267|C0015965|C0004339|C1704788|C0546816|C0168634|G0000000|C1442061|G0000000|C0150312|C0205087|G0000000|C0011100|C0301630|G0000000|C0042149|C1140999|C0150312|C0015965|C0039231|C0205322|G0000000|C1442061|G0000000|C0450371
80 ||| Results ||| 3.17 ||| The Kaplan-Meier survival curves for the time from induction to delivery did not differ between the groups (Fig.,kaplan-meier survival curves time induction delivery fig,G0000000|C0038952|C0205134|C0040223|C0205263|C0011209|C0349966
"93 ||| Discussion ||| 4.8 ||| The frequency of uterine hyperstimulation was low in the present study, with no significant difference between the groups.",frequency uterine hyperstimulation low study difference,C0376249|C0042149|G0000000|C0205251|C0557651|C1705241
"97 ||| Discussion ||| 4.12 ||| There were no cases of severe neonatal morbidity, neonatal death, severe maternal morbidity, or maternal death in the present study, which is consistent with the results of other studies [3].",severe neonatal morbidity neonatal death severe maternal morbidity maternal death study consistent studies 3,C0205082|C1552240|C0026538|C1552240|C0011065|C0205082|C2347083|C0026538|C2347083|C0011065|C0557651|C0332290|C0947630|G0000000
"12 ||| Introduction ||| 1.3 ||| The effectiveness of misoprostol is no longer questioned, although the ideal dose and route of administration remain to be defined [3][4][5][6][7][8][9][10].",effectiveness misoprostol questioned ideal dose route administration remain defined 345678910,C1280519|C0085174|C1522634|C1512612|C0178602|C0013153|C0001554|G0000000|C1704788|G0000000
"99 ||| Discussion ||| 4.14 ||| The Cochrane review [3] reported a greater need for oxytocin in women using oral misoprostol (57%) than in those with vaginal administration (51%), a finding that is in agreement with the results from another randomized controlled trial [13].",cochrane review 3 reported oxytocin women oral misoprostol 57% vaginal administration 51% finding agreement randomized controlled trial 13,G0000000|C0282443|G0000000|C0684224|C0030095|C0043210|C0442027|C0085174|C0450371|C0042232|C0001554|C0450371|C0037088|C0680240|C0034656|C2587213|C0008976|C0450371
"98 ||| Discussion ||| 4.13 ||| Likewise, no difference between the 2 groups was found in the need for oxytocin augmentation.",likewise difference 2 oxytocin augmentation,G0000000|C1705241|G0000000|C0030095|C1293122
"92 ||| Discussion ||| 4.7 ||| However, in the randomized controlled trial [8], the frequency of vaginal delivery not achieved within 24 hours was 5.9% for the oral solution and 46% for the vaginal tablets.",randomized controlled trial 8 frequency vaginal delivery achieved 24 hours 5 9% oral solution 46% vaginal tablets,C0034656|C2587213|C0008976|G0000000|C0376249|C0042232|C0011209|G0000000|C0450371|C0439227|G0000000|G0000000|C0442027|C0037633|C0450371|C0042232|C0039225
"48 ||| Materials and methods ||| 2.30 ||| Hypertonia/hypersystole was defined as uterine contractions for at least 2 minutes, tachysystole as 6 or more uterine contractions during 2 consecutive 10-minute periods, and uterine hyperstimulation as tachysystole or hypersystole/hypertonia associated with a nonreassuring FHR pattern [21].",hypertonia/hypersystole defined uterine contractions 2 minutes tachysystole 6 uterine contractions 2 consecutive 10-minute periods uterine hyperstimulation tachysystole hypersystole/hypertonia nonreassuring fhr pattern 21,C0026826|C1704788|C0042149|C1140999|G0000000|C0439232|C2985339|G0000000|C0042149|C1140999|G0000000|C1707491|C0450371|C0439531|C0042149|G0000000|C2985339|C0026826|G0000000|G0000000|C0449774|C0450371
53 ||| Materials and methods ||| 2.35 ||| Induction was considered to have failed when labor failed to begin and/or the Bishop score remained at 6 or less following administration of 8 vaginal tablets or 1 hour after the 48th dose of the oral solution.,induction considered failed labor failed and/or bishop score remained 6 administration 8 vaginal tablets 1 hour 48th dose oral solution,C0205263|C0750591|C0231175|C0022864|C0231175|G0000000|C1551458|C0449820|G0000000|G0000000|C0001554|G0000000|C0042232|C0039225|G0000000|C0439227|G0000000|C0178602|C0442027|C0037633
4 |||  ||| 0.4 ||| Risk ratios (RR) and 95% confidence intervals (CIs) were calculated for maternal and perinatal outcomes.,risk ratios rr 95% confidence intervals cis calculated maternal perinatal outcomes,C0035647|C0456603|G0000000|C0450371|C0237529|C1272706|C1504308|C0444686|C2347083|C0178795|C1274040
"103 ||| Discussion ||| 4.18 ||| With respect to the remaining outcomes (epidural analgesia and instrumental vaginal delivery), no significant differences were found, in agreement with the results of the Cochrane review [3].",respect remaining outcomes epidural analgesia instrumental vaginal delivery differences agreement cochrane review 3,C0679133|C1527428|C1274040|C0228134|C0002766|G0000000|C0042232|C0011209|C1705241|C0680240|G0000000|C0282443|G0000000
37 ||| Materials and methods ||| 2.19 ||| The study medications and placebos were packaged by the pharmaceutical company in identical boxes numbered sequentially from 1 to 200 in accordance with the randomization list.,study medications placebos packaged pharmaceutical company identical boxes numbered sequentially 1 200 randomization list,C0557651|C0013227|C0032042|C0030176|C0031336|C0683757|C0205280|C0179400|C0449788|G0000000|G0000000|C1442061|C0034656|C0745732
"42 ||| Materials and methods ||| 2.24 ||| Secondary outcomes were vaginal delivery not achieved within 24 hours, uterine hyperstimulation, cesarean delivery, severe neonatal morbidity (neonatal seizures and/or asphyxia) or perinatal death, and severe maternal morbidity (uterine rupture, sepsis, and/or admission to the intensive care unit) or maternal death.",secondary outcomes vaginal delivery achieved 24 hours uterine hyperstimulation cesarean delivery severe neonatal morbidity neonatal seizures and/or asphyxia perinatal death severe maternal morbidity uterine rupture sepsis and/or admission intensive care unit maternal death,C0027627|C1274040|C0042232|C0011209|G0000000|C0450371|C0439227|C0042149|G0000000|C3841297|C0011209|C0205082|C1552240|C0026538|C1552240|C0036572|G0000000|C0004044|C0178795|C0011065|C0205082|C2347083|C0026538|C0042149|C1881712|C0036690|G0000000|C0184666|C0162425|C1947933|C0439148|C2347083|C0011065
107 ||| Discussion ||| 4.22 ||| Another study [24] reported a satisfaction rate of approximately 85% with a sublingual solution.,study 24 reported satisfaction rate 85% sublingual solution,C0557651|C0450371|C0684224|C0242428|C0871208|C0450371|C0001565|C0037633
"94 ||| Discussion ||| 4.9 ||| This finding is consistent with other reports [3,7,9,11,12,17,23,25].",finding consistent reports 3 7 9 11 12 17 23 25,C0037088|C0332290|C0684224|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371
101 ||| Discussion ||| 4.16 ||| No cases of uterine hypertonia occurred.,uterine hypertonia occurred,C0042149|C0026826|C1709305
"110 ||| Acknowledgments ||| 5.1 ||| The Instituto de Medicina Integral Professor Fernando Figueira, where the study was carried out, is a private, nonprofit healthcare organization based in Recife, Pernambuco, Brazil.",instituto de medicina integral professor fernando figueira study carried private nonprofit healthcare organization based recife pernambuco brazil,G0000000|C0011198|G0000000|C0443238|C0599518|G0000000|G0000000|C0557651|C0206243|C0033175|C0029247|C0086388|C0029237|C1527178|G0000000|G0000000|C0006137
"95 ||| Discussion ||| 4.10 ||| The rate of cesarean deliveries was similar in the 2 groups, in concordance with a Cochrane review [3].",rate cesarean deliveries 2 concordance cochrane review 3,C0871208|C3841297|C0011209|G0000000|C0680240|G0000000|C0282443|G0000000
"59 ||| Materials and methods ||| 2.41 ||| To determine the normality of numeric variables, the Kolmogorov-Smirnov test was used.",determine normality numeric variables kolmogorov-smirnov test,G0000000|C0949333|C0237753|C0439828|G0000000|C0022885
"111 ||| Acknowledgments ||| 5.2 ||| The Institute did not interfere with the study design or analysis but covered all the costs involved in conducting the study, including the purchase of medication.",institute interfere study design analysis covered costs involved conducting study including purchase medication,C0021622|C0521102|C0557651|C1707689|C0002778|C0439844|C0010186|C1314939|C0004927|C0557651|C0332257|C0870238|C0013227
82 ||| Results ||| 3.19 ||| There were no episodes of shivering or diarrhea.,episodes shivering diarrhea,C0332189|C0036973|C0011991
"50 ||| Materials and methods ||| 2.32 ||| If the pattern persisted, tocolysis was performed using 0.25 mg of subcutaneous terbutaline [1].",pattern persisted tocolysis performed 0 25 subcutaneous terbutaline 1,C0449774|G0000000|C0040348|C0884358|G0000000|C0450371|C0443315|C0039542|G0000000
"56 ||| Materials and methods ||| 2.38 ||| Categorical variables were compared in contingency tables using the χ 2 test of association and the Fisher exact test, as appropriate.",categorical variables compared contingency tables 2 test association fisher exact test,C0683312|C0439828|C1707455|C1701901|C0039224|G0000000|C0022885|C0004083|C0325045|C2828393|C0022885
"73 ||| Results ||| 3.10 ||| Of the 92 women who required oxytocin,   44 (47.8%) delivered within 24 hours in the oral group and 48 (52.2%) in the vaginal group (P = 0.69).",92 women required oxytocin 44 47 8% delivered 24 hours oral 48 52 2% vaginal = 0 69,C0450371|C0043210|C1514873|C0030095|C0450371|C0450371|G0000000|C1705822|C0450371|C0439227|C0442027|C0450371|C0450371|G0000000|C0042232|G0000000|G0000000|C0450371
21 ||| Materials and methods ||| 2.3 ||| All participants voluntarily agreed to take part in the trial and gave their written informed consent.,participants voluntarily agreed trial written informed consent,C0679646|G0000000|C3641827|C0008976|C0043266|C1522154|C1511481
"36 ||| Materials and methods ||| 2.18 ||| The placebo and misoprostol formulations for each route of administration contained the same ingredients, except for the presence of the active substance, and were identical in appearance, color, taste, and shape.",placebo misoprostol formulations route administration contained ingredients presence active substance identical appearance color taste shape,C0032042|C0085174|C0524527|C0013153|C0001554|C0332256|C1550600|C0150312|C0205177|C0439861|C0205280|C0233426|C0009393|C0039336|C0332479
"105 ||| Discussion ||| 4.20 ||| The respective values in the present study are similar to those reported previously [9,17,24], with the exception of the findings from the first published randomized controlled trial [8] comparing an oral misoprostol solution with vaginal misoprostol and those from another study [16] that investigated the oral solution alone.",respective values study reported 9 17 24 exception findings published randomized controlled trial 8 comparing oral misoprostol solution vaginal misoprostol study 16 investigated oral solution,G0000000|C0042295|C0557651|C0684224|G0000000|C0450371|C0450371|C1554961|C2607943|C0034037|C0034656|C2587213|C0008976|G0000000|C1707455|C0442027|C0085174|C0037633|C0042232|C0085174|C0557651|C0450371|C1292732|C0442027|C0037633
41 ||| Materials and methods ||| 2.23 ||| The primary outcome was vaginal delivery not achieved within 12 hours.,primary outcome vaginal delivery achieved 12 hours,C0205225|C1274040|C0042232|C0011209|G0000000|C0450371|C0439227
69 ||| Results ||| 3.6 ||| The 2 groups were not significantly different in terms of vaginal delivery not achieved within 12 hours (P = 0.45) ( Table 2).,2 terms vaginal delivery achieved 12 hours = 0 45 table 2,G0000000|C0233324|C0042232|C0011209|G0000000|C0450371|C0439227|G0000000|G0000000|C0450371|C0039224|G0000000
75 ||| Results ||| 3.12 ||| Epidural analgesia was required for delivery in 1 patient in the oral misoprostol solution group only.,epidural analgesia required delivery 1 patient oral misoprostol solution,C0228134|C0002766|C1514873|C0011209|G0000000|C0030705|C0442027|C0085174|C0037633
"104 ||| Discussion ||| 4.19 ||| The mean time from the beginning of induction to the onset of labor, from the beginning of induction to vaginal delivery, and from the onset of labor to vaginal delivery did not differ between the 2 groups.",time induction onset labor induction vaginal delivery onset labor vaginal delivery 2,C0040223|C0205263|C0206132|C0022864|C0205263|C0042232|C0011209|C0206132|C0022864|C0042232|C0011209|G0000000
"72 ||| Results ||| 3.9 ||| The 2 groups did not differ with respect to having an unfavorable cervix after 12 and 24 hours, induction failure, and requirement for oxytocin augmentation (Table 2).",2 respect unfavorable cervix 12 24 hours induction failure requirement oxytocin augmentation table 2,G0000000|C0679133|C3640815|C0007874|C0450371|C0450371|C0439227|C0205263|C0231174|C1514873|C0030095|C1293122|C0039224|G0000000
63 ||| Materials and methods ||| 2.45 ||| Women delivering by cesarean delivery were considered censored at the time of the cesarean delivery.,women delivering cesarean delivery considered censored time cesarean delivery,C0043210|C0308779|C3841297|C0011209|C0750591|C3889990|C0040223|C3841297|C0011209
10 ||| Introduction ||| 1.1 ||| Misoprostol is one of the most common methods used to induce labor and can be administered by various routes and using several treatment regimens.,misoprostol common methods induce labor administered routes treatment regimens,C0085174|C0205214|C0025663|C0205263|C0022864|C1521801|C0449444|C0039798|C2945654
"51 ||| Materials and methods ||| 2.33 ||| In cases of uterine hyperstimulation, a cesarean delivery was performed as soon as possible.",uterine hyperstimulation cesarean delivery performed,C0042149|G0000000|C3841297|C0011209|C0884358
108 ||| Discussion ||| 4.23 ||| The present results show that the efficacy and safety of a titrated oral misoprostol solution are similar to those found with vaginal administration of a 25-μg dose every 6 hours.,efficacy safety titrated oral misoprostol solution vaginal administration 25-g dose 6 hours,C1280519|C0036043|C1883350|C0442027|C0085174|C0037633|C0042232|C0001554|C0450371|C0178602|G0000000|C0439227
68 ||| Results ||| 3.5 ||| There were no significant differences in the baseline characteristics of the 2 treatment groups ( Table 1).,differences baseline characteristics 2 treatment table 1,C1705241|C0168634|C1521970|G0000000|C0039798|C0039224|G0000000
"64 ||| Results ||| 3.1 ||| During the study period, 450 women were referred to the participating hospitals for labor induction (Fig.",study period 450 women referred participating hospitals labor induction fig,C0557651|C0439531|C1442061|C0043210|C0205543|C0679823|C0019994|C0022864|C0205263|C0349966
112 ||| Conflict of interest ||| 6.1 ||| The authors have no conflicts of interest.,authors conflicts,C3812881|C0009671
"11 ||| Introduction ||| 1.2 ||| The frequency of induced births depends on the country and region, with an estimated average of 20% of births [1][2][3][4][5][6][7][8].",frequency induced births depends country region estimated average 20% births 12345678,C0376249|C0205263|C0005615|C0725813|C0454664|C0017446|C0750572|C1510992|C0450371|C0005615|G0000000
81 ||| Results ||| 3.18 ||| The frequency of adverse effects was similar in the 2 groups (Table 4).,frequency adverse effects 2 table 4,C0376249|G0000000|C1280500|G0000000|C0039224|G0000000
"55 ||| Materials and methods ||| 2.37 ||| For data collection and analysis, the groups were initially identified as A or B, and both the statistician and the investigators were blinded with respect to the allocated group until the analysis was concluded.",data collection analysis initially identified statistician investigators blinded respect allocated analysis concluded,C1511726|C1516698|C0002778|C0205265|C0205396|C0334957|C0035173|C0150108|C0679133|G0000000|C0002778|C0917903
102 ||| Discussion ||| 4.17 ||| The Cochrane review [3] found lower rates of uterine hyperstimulation with no change in the FHR with the use of oral misoprostol compared with vaginal tablets.,cochrane review 3 lower rates uterine hyperstimulation change fhr oral misoprostol compared vaginal tablets,G0000000|C0282443|G0000000|C0441994|C0871208|C0042149|G0000000|C0392747|G0000000|C0442027|C0085174|C1707455|C0042232|C0039225
"27 ||| Materials and methods ||| 2.9 ||| Patients with uterine scar, abnormal fetal well-being test, fetal abnormalities, restricted fetal growth, genital bleeding related to placental abnormalities, or contraindications to vaginal delivery were excluded.",patients uterine scar abnormal fetal well-being test fetal abnormalities restricted fetal growth genital bleeding placental abnormalities contraindications vaginal delivery excluded,C0030705|C0042149|C0241158|C0205161|C0015965|C0018684|C0022885|C0015965|C0000768|C0443288|C0015965|C0018270|C0559522|C0019080|C0032043|C0000768|C0079164|C0042232|C0011209|C1554077
"15 ||| Introduction ||| 1.6 ||| However, other studies [11][12][13][14][15] have failed to confirm the superiority of this regimen.",studies 1112131415 failed confirm superiority regimen,C0947630|G0000000|C0231175|C0521093|C0680218|C0040808
"78 ||| Results ||| 3.15 ||| No significant difference was found between the 2 groups with respect to the mean time from the beginning of induction to the onset of labor (oral misoprostol [n = 83], 16.4 ± 12.9 hours; vaginal misoprostol [n = 88], 14.5 ± 11.3 hours; P = 0.31).",difference 2 respect time induction onset labor oral misoprostol = 83 16 4 12 9 hours vaginal misoprostol = 88 14 5 11 3 hours = 0 31,C1705241|G0000000|C0679133|C0040223|C0205263|C0206132|C0022864|C0442027|C0085174|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0439227|C0042232|C0085174|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0439227|G0000000|G0000000|C0450371
"32 ||| Materials and methods ||| 2.14 ||| The medication used in the study (oral misoprostol solution, vaginal misoprostol tablets, and the respective placebos) was purchased by IMIP from Hebron S/A Indústrias Químicas e Farmacêuticas (Caruaru, Pernambuco, Brazil).",medication study oral misoprostol solution vaginal misoprostol tablets respective placebos purchased imip hebron s/a indstrias qumicas farmacuticas caruaru pernambuco brazil,C0013227|C0557651|C0442027|C0085174|C0037633|C0042232|C0085174|C0039225|G0000000|C0032042|C0870238|G0000000|G0000000|C0565930|G0000000|G0000000|G0000000|G0000000|G0000000|C0006137
35 ||| Materials and methods ||| 2.17 ||| The oral solution was prepared in 100 mL bottles (2 μg/mL of misoprostol).,oral solution prepared 100 bottles 2 g/ml misoprostol,C0442027|C0037633|C4082130|C1442061|C0179376|G0000000|C1300565|C0085174
"58 ||| Materials and methods ||| 2.40 ||| For discrete variables and those without normal distribution, the MannWhitney U test was used.",discrete variables normal distribution mannwhitney test,C0443299|C0439828|C0205307|C0520511|G0000000|C0022885
"49 ||| Materials and methods ||| 2.31 ||| If tachysystole was detected, the woman was advised to lie on her left side and treated with intravenous hydration (1000 mL).",tachysystole detected woman advised lie left treated intravenous hydration 1000,C2985339|C0442726|C0043210|G0000000|G0000000|C0205091|C1522326|C0348016|C1321013|G0000000
"90 ||| Discussion ||| 4.5 ||| This finding differs drastically from the results of the present study, where the frequency of vaginal delivery not achieved within 12 hours was 81% in the group receiving misoprostol via the oral route.",finding differs drastically study frequency vaginal delivery achieved 12 hours 81% receiving misoprostol oral route,C0037088|G0000000|G0000000|C0557651|C0376249|C0042232|C0011209|G0000000|C0450371|C0439227|C0450371|C1514756|C0085174|C0442027|C0013153
16 ||| Introduction ||| 1.7 ||| A lower-dose regimen with shorter dosing intervals seems to be in accordance with the pharmacokinetics of oral compared with vaginal misoprostol [8][9][10].,lower-dose regimen shorter dosing intervals pharmacokinetics oral compared vaginal misoprostol 8910,C0445550|C0040808|C1282927|G0000000|C1272706|C0031327|C0442027|C1707455|C0042232|C0085174|G0000000
"14 ||| Introduction ||| 1.5 ||| In an open randomized clinical trial [8], a titrated oral misoprostol solution was shown to be of exceptional benefit, with a lower rate of uterine hyperstimulation and higher rates of nausea and vaginal delivery in the oral solution group compared with vaginal misoprostol.",randomized clinical trial 8 titrated oral misoprostol solution exceptional benefit lower rate uterine hyperstimulation rates nausea vaginal delivery oral solution compared vaginal misoprostol,C0034656|C0205210|C0008976|G0000000|C1883350|C0442027|C0085174|C0037633|C1554961|C0814225|C0441994|C0871208|C0042149|G0000000|C0871208|C0027497|C0042232|C0011209|C0442027|C0037633|C1707455|C0042232|C0085174
"24 ||| Materials and methods ||| 2.6 ||| Assuming these rates, a sample of 184 women would be needed to achieve a significance level of 5% and a statistical power of 80%.",assuming rates sample 184 women achieve significance level 5% statistical power 80%,G0000000|C0871208|C0370003|C1442061|C0043210|G0000000|C0237881|C0441889|G0000000|C0038215|C0032863|C0450371
"79 ||| Results ||| 3.16 ||| Likewise, there was no significant difference in the mean time from the beginning of induction to vaginal delivery (oral misoprostol [n = 59], 22.9 ± 14.9 hours; vaginal misoprostol [n = 63], 22.3 ± 13.0 hours; P = 0.81) and in the mean time between the onset of labor and vaginal delivery (oral misoprostol [n = 59], 7.05 ± 4.65 hours; vaginal misoprostol [n = 63], 6.98 ±3.83 hours; P = 0.93).",likewise difference time induction vaginal delivery oral misoprostol = 59 22 9 14 9 hours vaginal misoprostol = 63 22 3 13 0 hours = 0 81 time onset labor vaginal delivery oral misoprostol = 59 7 05 4 65 hours vaginal misoprostol = 63 6 98 3 83 hours = 0 93,G0000000|C1705241|C0040223|C0205263|C0042232|C0011209|C0442027|C0085174|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0439227|C0042232|C0085174|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0439227|G0000000|G0000000|C0450371|C0040223|C0206132|C0022864|C0042232|C0011209|C0442027|C0085174|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|C0439227|C0042232|C0085174|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|C0439227|G0000000|G0000000|C0450371
7 |||  ||| 0.7 ||| Approximately 70% of the women preferred the oral solution.,70% women preferred oral solution,C0450371|C0043210|C0558295|C0442027|C0037633
9 |||  ||| 0.9 ||| ClinicalTrial.gov: NCT00 992524,clinicaltrial gov nct00 992524,G0000000|C1419208|G0000000|G0000000
"38 ||| Materials and methods ||| 2.20 ||| Each box contained a set of 8 vaginal tablets (placebo or 25 μg of misoprostol) and 16 bottles containing 100 mL of the oral solution (placebo or 2 μg/mL of misoprostol), in the following combinations: oral misoprostol solution with placebo tablets, and misoprostol tablets with oral placebo solution.",box contained set 8 vaginal tablets placebo 25 misoprostol 16 bottles 100 oral solution placebo 2 g/ml misoprostol combinations oral misoprostol solution placebo tablets misoprostol tablets oral placebo solution,C0179400|C0332256|C0036849|G0000000|C0042232|C0039225|C0032042|C0450371|C0085174|C0450371|C0179376|C1442061|C0442027|C0037633|C0032042|G0000000|C1300565|C0085174|C0453882|C0442027|C0085174|C0037633|C0032042|C0039225|C0085174|C0039225|C0442027|C0032042|C0037633
96 ||| Discussion ||| 4.11 ||| No difference was found between the groups with respect to the indications for cesarean delivery.,difference respect indications cesarean delivery,C1705241|C0679133|C0392360|C3841297|C0011209
"2 |||  ||| 0.2 ||| Methods: A randomized, triple-blind, multicenter clinical trial was conducted between March 2010 and June 2011.",methods randomized triple-blind multicenter clinical trial conducted march 2010 june 2011,C0025663|C0034656|C0205174|C0439743|C0205210|C0008976|C0004927|C3829202|G0000000|C3829443|G0000000
76 ||| Results ||| 3.13 ||| There were no differences between the group in terms of vaginal delivery and forceps delivery.,differences terms vaginal delivery forceps delivery,C1705241|C0233324|C0042232|C0011209|C0016533|C0011209
60 ||| Materials and methods ||| 2.42 ||| Risk ratios (RR) and 95% confidence intervals (CIs) were calculated.,risk ratios rr 95% confidence intervals cis calculated,C0035647|C0456603|G0000000|C0450371|C0237529|C1272706|C1504308|C0444686
"100 ||| Discussion ||| 4.15 ||| With reference to uterine hyperactivity, no statistically significant differences in the rate of tachysystole were found in the present study.",reference uterine hyperactivity statistically differences rate tachysystole study,C1514811|C0042149|C0424295|C0038215|C1705241|C0871208|C2985339|C0557651
20 ||| Materials and methods ||| 2.2 ||| The study was approved by the Institutional Review Board at IMIP.,study approved institutional review board imip,C0557651|C0205540|C0018704|C0282443|C0972401|G0000000
"71 ||| Results ||| 3.8 ||| The main reasons for performing a   cesarean delivery were protracted active phase, induction failure, nonreassuring FHR, and uterine hyperstimulation, with no significant differences between the groups (Table 3).",main reasons performing cesarean delivery protracted active phase induction failure nonreassuring fhr uterine hyperstimulation differences table 3,C0205225|C0392360|C0884358|C3841297|C0011209|G0000000|C0205177|C0205390|C0205263|C0231174|G0000000|G0000000|C0042149|G0000000|C1705241|C0039224|G0000000
"29 ||| Materials and methods ||| 2.11 ||| All women included in the study were accompanied according to standard routine for their clinical condition, and fetal well-being was evaluated by intermittent fetal auscultation or intrapartum cardiotocography [19].",women included study accompanied standard routine clinical condition fetal well-being evaluated intermittent fetal auscultation intrapartum cardiotocography 19,C0043210|C0332257|C0557651|G0000000|C1442989|C0205547|C0205210|C0012634|C0015965|C0018684|C0220825|C0205267|C0015965|C0004339|C0456337|C0007208|C0450371
"44 ||| Materials and methods ||| 2.26 ||| Neonatal outcomes were meconium-stained amniotic fluid, 1-minute and 5-minute Apgar scores of less than 7, admission to the neonatal intensive care unit, neonatal encephalopathy, and perinatal death [20].",neonatal outcomes meconium-stained amniotic fluid 1-minute 5-minute apgar scores 7 admission neonatal intensive care unit neonatal encephalopathy perinatal death 20,C1552240|C1274040|C1112318|C0002630|C0005889|C0439232|C0439232|C0741195|C0449820|G0000000|C0184666|C1552240|C0162425|C1947933|C0439148|C1552240|C0006111|C0178795|C0011065|C0450371
"91 ||| Discussion ||| 4.6 ||| In the present study, similar rates of vaginal delivery not achieved within 24 hours were found for the oral solution (63%) and the vaginal tablets (58%) of misoprostol, a result that is consistent with the findings from most other studies [3,7,12,17,24].",study rates vaginal delivery achieved 24 hours oral solution 63% vaginal tablets 58% misoprostol result consistent findings studies 3 7 12 17 24,C0557651|C0871208|C0042232|C0011209|G0000000|C0450371|C0439227|C0442027|C0037633|C0450371|C0042232|C0039225|C0450371|C0085174|C1274040|C0332290|C2607943|C0947630|G0000000|G0000000|C0450371|C0450371|C0450371
"62 ||| Materials and methods ||| 2.44 ||| A Kaplan-Meier survival analysis was performed to assess the time from the beginning of induction until delivery, with the log rank test used to compare the areas under the curve for the 2 routes of administration.",kaplan-meier survival analysis performed assess time induction delivery log rank test compare curve 2 routes administration,G0000000|C0038952|C0002778|C0884358|C1516048|C0040223|C0205263|C0011209|C1708728|C0699794|C0022885|C1707455|C0205134|G0000000|C0449444|C0001554
"87 ||| Discussion ||| 4.2 ||| Several studies [8,17,22,23] have evaluated the frequency of vaginal delivery not achieved within 12 hours among women who received oral titrated versus vaginal misoprostol for labor induction.",studies 8 17 22 23 evaluated frequency vaginal delivery achieved 12 hours women received oral titrated versus vaginal misoprostol labor induction,C0947630|G0000000|C0450371|C0450371|C0450371|C0220825|C0376249|C0042232|C0011209|G0000000|C0450371|C0439227|C0043210|C1514756|C0442027|C1883350|G0000000|C0042232|C0085174|C0022864|C0205263
"39 ||| Materials and methods ||| 2.21 ||| The initial dose of the oral solution was 20 μg/hour (10 mL/hour) of misoprostol or 10 mL/hour of placebo for the first 6 hours, which was increased by 20 μg/hour (10 mL/hour) every 6 hours by the attending nurse with a calibrated medicine cup if labor was not induced (maximum dose 80 μg/hour or until the 48th dose).",initial dose oral solution 20 g/hour 10 ml/hour misoprostol 10 ml/hour placebo 6 hours increased 20 g/hour 10 ml/hour 6 hours attending nurse calibrated medicine cup labor induced maximum dose 80 g/hour 48th dose,C0205265|C0178602|C0442027|C0037633|C0450371|C0439267|C0450371|C0439526|C0085174|C0450371|C0439526|C0032042|G0000000|C0439227|C0205217|C0450371|C0439267|C0450371|C0439526|G0000000|C0439227|C1547429|C0028661|G0000000|C0013227|C1533124|C0022864|C0205263|C0806909|C0178602|C0450371|C0439267|G0000000|C0178602
52 ||| Materials and methods ||| 2.34 ||| Labor was defined as the presence of 3 uterine contractions in 10 minutes with cervical changes [2].,labor defined presence 3 uterine contractions 10 minutes cervical 2,C0022864|C1704788|C0150312|G0000000|C0042149|C1140999|C0450371|C0439232|C0027530|G0000000
18 ||| Introduction ||| 1.9 ||| The present study was conducted to determine the effectiveness and safety of a titrated oral homogenized misoprostol solution compared with vaginal misoprostol tablets for the induction of labor in full-term live pregnancies.,study conducted determine effectiveness safety titrated oral homogenized misoprostol solution compared vaginal misoprostol tablets induction labor full-term live pregnancies,C0557651|C0004927|G0000000|C1280519|C0036043|C1883350|C0442027|G0000000|C0085174|C0037633|C1707455|C0042232|C0085174|C0039225|C0205263|C0022864|C1547236|C1548795|C0032961
109 ||| Discussion ||| 4.24 ||| Further studies should be conducted before use of the oral misoprostol solution can be recommended in routine practice; future studies should also specifically address the issue of patient preference and satisfaction.,studies conducted oral misoprostol solution recommended routine practice future studies address issue patient preference satisfaction,C0947630|C0004927|C0442027|C0085174|C0037633|C0034866|C0205547|C0237607|C0016884|C0947630|C0376649|C0033213|C0030705|C0558295|C0242428
"23 ||| Materials and methods ||| 2.5 ||| In a pilot study [16] of the titrated oral solution, 52% of women did not have a vaginal delivery within 12 hours of misoprostol administration, and the respective rate with vaginal misoprostol was 73% in another study conducted at IMIP [17].",pilot study 16 titrated oral solution 52% women vaginal delivery 12 hours misoprostol administration respective rate vaginal misoprostol 73% study conducted imip 17,C0473169|C0557651|C0450371|C1883350|C0442027|C0037633|C0450371|C0043210|C0042232|C0011209|C0450371|C0439227|C0085174|C0001554|G0000000|C0871208|C0042232|C0085174|C0450371|C0557651|C0004927|G0000000|C0450371
"77 ||| Results ||| 3.14 ||| No woman died, no cases of severe maternal or perinatal morbidity or perinatal death occurred, and there was no hypertonia or uterine rupture.",woman died severe maternal perinatal morbidity perinatal death occurred hypertonia uterine rupture,C0043210|C0011065|C0205082|C2347083|C0178795|C0026538|C0178795|C0011065|C1709305|C0026826|C0042149|C1881712
57 ||| Materials and methods ||| 2.39 ||| Continuous variables with normal distribution were compared using t test.,continuous variables normal distribution compared test,C0549178|C0439828|C0205307|C0520511|C1707455|C0022885
"46 ||| Materials and methods ||| 2.28 ||| The indication for cesarean delivery and the times between the beginning of induction and the beginning of labor, between the beginning of induction and vaginal delivery, and between the beginning of labor and vaginal delivery were evaluated.",indication cesarean delivery times induction labor induction vaginal delivery labor vaginal delivery evaluated,C0392360|C3841297|C0011209|C0040223|C0205263|C0022864|C0205263|C0042232|C0011209|C0022864|C0042232|C0011209|C0220825
83 ||| Results ||| 3.20 ||| Perinatal outcomes were also similar in the 2 groups (Table 5).,perinatal outcomes 2 table 5,C0178795|C1274040|G0000000|C0039224|G0000000
"6 |||  ||| 0.6 ||| No differences were found in terms of uterine hyperstimulation, unfavorable cervix at 12 and 24 hours, oxytocin augmentation , tachysystole, epidural analgesia, adverse effects, and perinatal outcome.",differences terms uterine hyperstimulation unfavorable cervix 12 24 hours oxytocin augmentation tachysystole epidural analgesia adverse effects perinatal outcome,C1705241|C0233324|C0042149|G0000000|C3640815|C0007874|C0450371|C0450371|C0439227|C0030095|C1293122|C2985339|C0228134|C0002766|G0000000|C1280500|C0178795|C1274040
"86 ||| Discussion ||| 4.1 ||| In the present study, no significant differences in the evaluated outcomes were found when an oral misoprostol solution was compared with vaginal misoprostol tablets.",study differences evaluated outcomes oral misoprostol solution compared vaginal misoprostol tablets,C0557651|C1705241|C0220825|C1274040|C0442027|C0085174|C0037633|C1707455|C0042232|C0085174|C0039225
34 ||| Materials and methods ||| 2.16 ||| Vaginal tablets of misoprostol are commercially available in Brazil at a dose of 25 μg.,vaginal tablets misoprostol commercially brazil dose 25,C0042232|C0039225|C0085174|G0000000|C0006137|C0178602|C0450371
74 ||| Results ||| 3.11 ||| Tachysystole was only found in the oral misoprostol group (Table 2).,tachysystole oral misoprostol table 2,C2985339|C0442027|C0085174|C0039224|G0000000
13 ||| Introduction ||| 1.4 ||| The WHO [1] recommends 25 μg of oral misoprostol every 2 hours or 25 μg of vaginal misoprostol every 6 hours (strong recommendation).,1 recommends 25 oral misoprostol 2 hours 25 vaginal misoprostol 6 hours strong recommendation,G0000000|C0034866|C0450371|C0442027|C0085174|G0000000|C0439227|C0450371|C0042232|C0085174|G0000000|C0439227|C0442821|C0034866
"5 |||  ||| 0.5 ||| Results: The frequencies of vaginal delivery not achieved within 12 hours (RR 0.87; 95% CI, 0.62-1.22) and within 24 hours (RR 1.11; 95% CI, 0.83-1.49) were similar in the 2 groups.",frequencies vaginal delivery achieved 12 hours rr 0 87 95% ci 0 62-1 22 24 hours rr 1 11 95% ci 0 83-1 49 2,C0439603|C0042232|C0011209|G0000000|C0450371|C0439227|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371|C0450371|C0439227|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371|G0000000
1 |||  ||| 0.1 ||| Objective: To determine the efficacy and safety of a titrated oral misoprostol solution compared with vaginal mi-soprostol tablets for labor induction.,objective determine efficacy safety titrated oral misoprostol solution compared vaginal mi-soprostol tablets labor induction,C0018017|G0000000|C1280519|C0036043|C1883350|C0442027|C0085174|C0037633|C1707455|C0042232|C3810814|C0039225|C0022864|C0205263
"30 ||| Materials and methods ||| 2.12 ||| The randomization procedure was performed using Random Allocation version 1.0 (Isfahan University of Medical Sciences; Isfahan, Iran).",randomization procedure performed random allocation version 1 0 isfahan university medical sciences isfahan iran,C0034656|C0184661|C0884358|C0034656|C1706778|C0333052|G0000000|G0000000|G0000000|C0041740|C0199168|C0036397|G0000000|C0022065
"85 ||| Results ||| 3.22 ||| With respect to the mother's preference regarding the route of administration, 69.5% (95% CI, 62.6-75.8%) of the women reported that they would prefer the oral solution to the vaginal tablets should they need to use the drug to induce labor in a subsequent pregnancy.",respect mothers preference route administration 69 5% 95% ci 62 6-75 8% women reported prefer oral solution vaginal tablets drug induce labor subsequent pregnancy,C0679133|C0026591|C0558295|C0013153|C0001554|C0450371|G0000000|C0450371|C0008107|C0450371|C0450371|G0000000|C0043210|C0684224|G0000000|C0442027|C0037633|C0042232|C0039225|C0013227|C0205263|C0022864|C0332282|C0032961
"54 ||| Materials and methods ||| 2.36 ||| The statistical analysis was performed with Epi Info version 7 (Centers for Disease Control and Prevention, Atlanta, GA, USA), using the intention-to-treat principle.",statistical analysis performed epi info version 7 centers disease control prevention atlanta ga usa intention-to-treat principle,C0038215|C0002778|C0884358|G0000000|C1533716|C0333052|G0000000|C0205099|C0012634|C0243148|C0199176|C2993063|C0016993|C0041703|C0162425|G0000000
61 ||| Materials and methods ||| 2.43 ||| The P values for all tests were 2-tailed; P b 0.05 was considered statistically significant.,values tests 2-tailed 0 05 considered statistically,C0042295|C0022885|C0039259|G0000000|C0450371|C0750591|C0038215
67 ||| Results ||| 3.4 ||| There were no protocol violations.,protocol violations,C0442711|G0000000
"106 ||| Discussion ||| 4.21 ||| Approximately 70% of the women reported that they would prefer the oral misoprostol solution over the vaginal tablets, should labor have to be induced in a future pregnancy.",70% women reported prefer oral misoprostol solution vaginal tablets labor induced future pregnancy,C0450371|C0043210|C0684224|G0000000|C0442027|C0085174|C0037633|C0042232|C0039225|C0022864|C0205263|C0016884|C0032961
"28 ||| Materials and methods ||| 2.10 ||| Fetal well-being was evaluated by Doppler flow velocimetry, cardiotocography, and/or biophysical profile scoring, depending on the routine at each hospital.",fetal well-being evaluated doppler flow velocimetry cardiotocography and/or biophysical profile scoring depending routine hospital,C0015965|C0018684|C0220825|C0554756|C0806140|C0162462|C0007208|G0000000|C0005553|C1979963|C0449820|C0725813|C0205547|C0019994
"88 ||| Discussion ||| 4.3 ||| In previous reports [8,17,23], 68-74% of women exposed to vaginal misoprostol had not given birth at 12 hours compared with 85% in the present study.",previous reports 8 17 23 68-74% women exposed vaginal misoprostol birth 12 hours compared 85% study,C0205156|C0684224|G0000000|C0450371|C0450371|C0450371|C0043210|C0332157|C0042232|C0085174|C0005615|C0450371|C0439227|C1707455|C0450371|C0557651
"17 ||| Introduction ||| 1.8 ||| Although previous studies [8,11,12,14] have evaluated the use of a titrated misoprostol solution, none used a homogenized oral solution.",previous studies 8 11 12 14 evaluated titrated misoprostol solution homogenized oral solution,C0205156|C0947630|G0000000|C0450371|C0450371|C0450371|C0220825|C1883350|C0085174|C0037633|G0000000|C0442027|C0037633
25 ||| Materials and methods ||| 2.7 ||| This number was increased to 200 to allow for loss of follow-up.,increased 200 loss follow-up,C0205217|C1442061|C1517945|C0589120
8 |||  ||| 0.8 ||| Conclusion: A titrated oral misoprostol solution was as effective and safe for labor induction as vaginal misoprostol tablets.,conclusion titrated oral misoprostol solution effective safe labor induction vaginal misoprostol tablets,C1707478|C1883350|C0442027|C0085174|C0037633|C1280519|G0000000|C0022864|C0205263|C0042232|C0085174|C0039225
"31 ||| Materials and methods ||| 2.13 ||| Numbers from 1 to 200 were randomly allocated to 2 groups designated A and B, and the resulting lists were sent to the pharmaceutical company in charge of the drug preparation.",1 200 randomly allocated 2 designated lists pharmaceutical company charge drug preparation,G0000000|C1442061|G0000000|G0000000|G0000000|C1524084|C0745732|C0031336|C0683757|C0007961|C0013227|C1521827
"19 ||| Materials and methods ||| 2.1 ||| A multicenter randomized, triple-blind clinical trial was carried out at Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Policlínica e Maternidade Professor Arnaldo Marques, and Hospital Barão de Lucena, all in the city of Recife, Pernambuco, in northeastern Brazil, between March 1, 2010, andJune 30, 2011.",multicenter randomized triple-blind clinical trial carried instituto de medicina integral professor fernando figueira imip policlnica maternidade professor arnaldo marques hospital baro de lucena city recife pernambuco northeastern brazil march 1 2010 andjune 30 2011,C0439743|C0034656|C0205174|C0205210|C0008976|C0206243|G0000000|C0011198|G0000000|C0443238|C0599518|G0000000|G0000000|G0000000|G0000000|G0000000|C0599518|G0000000|G0000000|C0019994|G0000000|C0011198|G0000000|C0008848|G0000000|G0000000|C1709272|C0006137|C3829202|G0000000|G0000000|G0000000|C0450371|G0000000
"33 ||| Materials and methods ||| 2.15 ||| The quality of the medication was controlled by the batch number, according to protocols of the Brazilian pharmaceutical industry [18].",quality medication controlled batch protocols brazilian pharmaceutical industry 18,C0332306|C0013227|C2587213|C1550176|C0442711|C0238815|C0031336|C0021267|C0450371
"22 ||| Materials and methods ||| 2.4 ||| The sample size was calculated using OpenEpi version 2.3 (OpenEpi; Atlanta, GA, USA).",sample size calculated openepi version 2 3 openepi atlanta ga usa,C0370003|C0456389|C0444686|G0000000|C0333052|G0000000|G0000000|G0000000|C2993063|C0016993|C0041703
"66 ||| Results ||| 3.3 ||| Therefore, 200 women remained in the study, 100 of whom were randomly assigned to the oral misoprostol solution group and 100 to the vaginal misoprostol group.",200 women remained study 100 randomly assigned oral misoprostol solution 100 vaginal misoprostol,C1442061|C0043210|G0000000|C0557651|C1442061|G0000000|C1516050|C0442027|C0085174|C0037633|C1442061|C0042232|C0085174
"26 ||| Materials and methods ||| 2.8 ||| The inclusion criteria were single live pregnancy, pregnancy duration of 37 weeks or more, indication for labor induction (hypertension, premature rupture of membranes, diabetes, or pregnancy duration of 41 weeks or more), vertex presentation, estimated fetal weight of less than 4000 g according to ultrasonography, amniotic fluid index of more than 5 cm, and modified Bishop score of 6 or less.",inclusion criteria single live pregnancy pregnancy duration 37 weeks indication labor induction hypertension premature rupture membranes diabetes pregnancy duration 41 weeks vertex presentation estimated fetal weight 4000 ultrasonography amniotic fluid 5 cm modified bishop score 6,C0007637|C0243161|C0037179|C1548795|C0032961|C0032961|C0449238|C0450371|C0439230|C0392360|C0022864|C0205263|C0020538|C0151526|C1881712|C0025255|C0011847|C0032961|C0449238|C0450371|C0439230|C0230003|C0449450|C0750572|C0015965|C0005910|G0000000|C0041618|C0002630|C0005889|G0000000|G0000000|C0392747|C1551458|C0449820|G0000000
40 ||| Materials and methods ||| 2.22 ||| The vaginal tablet (25 μg misoprostol or placebo) was placed into the posterior fornix by the attending physician every 6 hours (maximum dose 200 μg or 8 tablets).,vaginal tablet 25 misoprostol placebo posterior fornix attending physician 6 hours maximum dose 200 8 tablets,C0042232|C0039225|C0450371|C0085174|C0032042|C0205095|C0152334|C1547429|C0031831|G0000000|C0439227|C0806909|C0178602|C1442061|G0000000|C0039225
"65 ||| Results ||| 3.2 ||| Of these, 203 met the inclusion criteria; however, 3 declined participation.",203 met inclusion criteria 3 declined participation,C1442061|C0268621|C0007637|C0243161|G0000000|G0000000|C0679823
"43 ||| Materials and methods ||| 2.25 ||| Other outcomes evaluated were unfavorable cervix after 12-24 hours, need for oxytocin augmentation, hypertonia/hypersystole, tachysystole, uterine rupture, epidural analgesia, instrumental vaginal delivery, and adverse effects (headache, nausea, vomiting, diarrhea, and postpartum hemorrhage).",outcomes evaluated unfavorable cervix 12-24 hours oxytocin augmentation hypertonia/hypersystole tachysystole uterine rupture epidural analgesia instrumental vaginal delivery adverse effects headache nausea vomiting diarrhea postpartum hemorrhage,C1274040|C0220825|C3640815|C0007874|C0450371|C0439227|C0030095|C1293122|C0026826|C2985339|C0042149|C1881712|C0228134|C0002766|G0000000|C0042232|C0011209|G0000000|C1280500|C0018681|C0027497|C0042963|C0011991|C0086839|C0019080
3 |||  ||| 0.3 ||| Women with a single gestation (n = 200) were randomized to receive a titrated oral misoprostol solution (initial misoprostol dose 20 μg/hour; dose increased by 20 μg/hour every 6 hours up to 80 μg/hour for a maximum of 48 doses) or vaginal misoprostol tablets (25 μg of misoprostol every 6 hours for a maximum of 8 doses).,women single gestation = 200 randomized receive titrated oral misoprostol solution initial misoprostol dose 20 g/hour dose increased 20 g/hour 6 hours 80 g/hour maximum 48 doses vaginal misoprostol tablets 25 misoprostol 6 hours maximum 8 doses,C0043210|C0037179|C0032961|G0000000|C1442061|C0034656|C1514756|C1883350|C0442027|C0085174|C0037633|C0205265|C0085174|C0178602|C0450371|C0439267|C0178602|C0205217|C0450371|C0439267|G0000000|C0439227|C0450371|C0439267|C0806909|C0450371|C0178602|C0042232|C0085174|C0039225|C0450371|C0085174|G0000000|C0439227|C0806909|G0000000|C0178602
